Hengrui Pharma's 'Dual AI' Combination Achieves Breakthrough in Refractory Chordoma: Phase II Study Published in JCO
May 22, 2026 18:14
CST Updated
19:40
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer